MET and non-small cell lung carcinoma: When the KRAS mutational status was ignored, expression of the following proteins was present in over half of the NSCLC patients (percentage of patients with positive expression of the protein in parenthesis): NQO1 (67.8%), survivin (75%), DNMT1 (74.6%), and c-MET (68.9%).